A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancerHaidy Nasief, X. Allen Li, Cheng Zheng et al.|npj Precision Oncology|2019Cited by 181
MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i>-mutated advanced pancreatic ductal adenocarcinoma (PDAC).Maahum Mehdi, Mandana Kamgar, Sakti Chakrabarti et al.|Journal of Clinical Oncology|2022Cited by 7
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case seriesMaahum Mehdi, Mandana Kamgar, Aniko Szabo et al.|Therapeutic Advances in Medical Oncology|2024Cited by 5
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, Thomas McFall, G. Aaron Hobbs et al.|Cancer Research|2025Cited by 3